Two different spectrofluorimetric methods for simultaneous determination of gemfibrozil and rosiglitazone in human plasma

Two accurate, reliable, and highly sensitive spectrofluorimetric methods were developed for simultaneous determination of binary mixture gemfibrozil and rosiglitazone in human plasma without prior separation steps. The first method is based on synchronous fluorescence spectrometry using double scans. At Δλ = 27 nm, gemfibrozil yields detectable signal that is independent of the presence of rosiglitazone. Similarly, at Δλ = 120 nm the signal of rosiglitazone is not influenced by the presence of gemfibrozil. Signals at two wavelengths, 301 (Δλ = 27 nm) and 368 nm (Δλ = 120 nm) vary linearly with gemfibrozil and rosiglitazone concentrations over the range 100–700 ng mL−1 (for gemfibrozil) and 20–140 ng mL−1 (for rosiglitazone), respectively. The limits of detection (LOD) were 2.3 and 2.72 ng mL−1 for gemfibrozil and rosiglitazone, respectively. The second method is based on the technique of simultaneous equations (Vierodtʹs method), in which 258 nm was selected as the excitation wavelength. Two equations are constructed based on the fact that at ( λ Em 2 = 302   nm of gemfibrozil) and ( λ Em 2 = 369   nm of rosiglitazone) the fluorescence of the mixture is the sum of the individual fluorescence of gemfibrozil and rosiglitazone. The limits of detection (LOD) were 28.1 and 23.63 ng mL−1 for gemfibrozil and rosiglitazone, respectively. The proposed methods were successfully applied for the determination of the two compounds in synthetic mixtures and in human plasma with a good recovery.